Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 399 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Initial Bolus Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

PeriOperative ISchemic Evaluation-3 Trial

NCT03505723
View directory record Official record
Conditions
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
Interventions
Tranexamic Acid, Placebo (Saline), Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
Drug · Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
9,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Weston, Florida • New York, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 2, 2026, 2:17 AM EDT
Recruiting Early Phase 1 Interventional

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

NCT06137040
View directory record Official record
Conditions
Asthma in Children, Asthma Attack
Interventions
Magnesium Sulfate within the first hour, No Magnesium sulfate within the first hour
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

NCT00043940
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia, Thrombosis
Interventions
bivalirudin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 2, 2026, 2:17 AM EDT
Terminated Not applicable Interventional Results available

Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

NCT01088997
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome
Interventions
Milrinone Lactate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 10 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 2, 2026, 2:17 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

NCT01093131
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Oral hydration, Oral sodium bicarbonate, Intravenous Hydration, Intravenous sodium bicarbonate
Other · Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 2, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Initial Local Anesthetic Dose With Continuous Interscalene Analgesia

NCT00672100
View directory record Official record
Conditions
Post-operative Pain
Interventions
Ropivacaine
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 2, 2026, 2:17 AM EDT
Recruiting Phase 3 Interventional

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

NCT01076764
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
13,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 82 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 2, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

ODSH + ICE Chemotherapy in Pediatric Solid Tumors

NCT02164097
View directory record Official record
Conditions
Recurrent Solid Tumor, Refractory Solid Tumor, Sarcoma, Wilms' Tumor, Neuroblastoma
Interventions
ODSH
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Early Phase 1 Interventional

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo

NCT04096170
View directory record Official record
Conditions
Hernia, Paraesophageal
Interventions
IV lidocaine, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

NCT03283202
View directory record Official record
Conditions
Diffuse B-Cell Lymphoma
Interventions
Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion, Vincristine, Prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Tampa, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 2, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Phase 4 Interventional

Insulin Therapy in the Hospital Comparing Two Protocols

NCT00841919
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine insulin, NPH insulin and regular insulin, lispro insulin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 2, 2026, 2:17 AM EDT
Recruiting Phase 2 Interventional

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

NCT04562129
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
Interventions
Interleukin-2, Ipilimumab, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 2, 2026, 2:17 AM EDT
Enrolling by invitation No phase listed Observational

Characterizing the EEG Signature of Fentanyl and Its Association With Drug Liking

NCT06699953
View directory record Official record
Conditions
Brain Activity Related to Opioid Administration, Brain Activity Related to Drug Liking
Interventions
Observational study in patients receiving fentanyl for surgery
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 2, 2026, 2:17 AM EDT
Terminated Not applicable Interventional

Early Versus Late Caffeine for ELBW Newborns

NCT02524249
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Apnea of Prematurity
Interventions
Caffeine, Placebo (dextrose)
Drug
Lead sponsor
Wayne State University
Other
Eligibility
Up to 4 Weeks
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 2, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

NCT00859833
View directory record Official record
Conditions
Obesity, Endothelial Dysfunction, Decreased Vascular Flow
Interventions
Adenosine, Regadenoson
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 88 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 2, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Lurbinectedin, Doxorubicin
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, placebo, oxaliplatin, folinic acid, fluorouracil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 2, 2026, 2:17 AM EDT
Withdrawn Phase 2 Interventional

Coronary Vasomotor Response After Riociguat Exposure

NCT01165931
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Riociguat (BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 2, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 2, 2026, 2:17 AM EDT